Completed PHASE3 INTERVENTIONAL 2-arm NCT00053677

Drug Treatment for Pathologic Gambling Disorder

Naltrexone Treatment in Pathologic Gambling Disorder

Sponsor: National Institute of Mental Health (NIMH)

Conditions Gambling

Updated 11 times since 2017 Last updated: Feb 21, 2023 Started: Dec 31, 2002 Primary completion: Nov 30, 2005 Completion: Nov 30, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Gambling, this trial is completed. The trial is conducted by National Institute of Mental Health (NIMH) and has accumulated 11 data snapshots since 2002. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

11 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Mar 2023 — Jul 2024 [monthly]

Completed PHASE3
Jan 2023 — Mar 2023 [monthly]

Completed PHASE3
Dec 2022 — Jan 2023 [monthly]

Completed PHASE3

▶ Show 6 earlier versions

Dec 2021 — Dec 2022 [monthly]

Completed PHASE3
Jan 2021 — Dec 2021 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Oct 2017 — Jun 2018 [monthly]

Completed PHASE3
Feb 2017 — Oct 2017 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Dec 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Institute of Mental Health (NIMH)
University of Chicago

Data source: University of Chicago

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Minneapolis, United States